AHAnn Katarina Haylett

Ann Katarina Haylett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ann Katarina Haylett has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Lesley Elizabeth Rhodes

    Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK

    15 shared publications
  • James V. Moore

    Cancer Research-UK Laser Oncology Group, Paterson Institute for Cancer Research, Wilmslow Rd, Manchester, UK

    4 shared publications
  • Anna Nicolaou

    Laboratory for Lipidomics and Lipid Biology, Division of Pharmacy and Optometry, School of Health Sciences, The University of Manchester, Manchester, UK

    3 shared publications
  • Desmond John Tobin

    Charles Institute of Dermatology, School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland

    3 shared publications
  • J.V. Moore

    CRC Experimental Radiation Oncology Group, Paterson Institute for Cancer Research, and

    3 shared publications
  • Karl Gledhill

    Centre for Skin Sciences, School of Life Sciences, University of Bradford, Bradford, UK

    3 shared publications

Latest Publications

  • British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018

    by T H Wong, C A Morton, N Collier, A Haylett, S Ibbotson, K E McKenna, R Mallipeddi, H Moseley, D C Seukeran, L E Rhodes, et al.


  • Evaluating patient responses to omalizumab in solar urticaria

    by Liezel L. Griffin, Ann K. Haylett, Lesley E. Rhodes


  • Adverse effects of topical photodynamic therapy: a consensus review and approach to management

    by S.H. Ibbotson, T.H. Wong, C.A. Morton, N.J. Collier, A. Haylett, K.E. McKenna, R. Mallipeddi, H. Moseley, L.E. Rhodes, D.C. Seukeran, et al.

    Topical photodynamic therapy (PDT) is widely used to effectively treat superficial non‐melanoma skin cancer and dysplasia. As with any therapeutic approach, the risk/benefit profile must be taken into account on an individual patient basis; in general, PDT is well tolerated. Historically, PDT‐induced pain has been a potentially limiting factor, but with optimisation of treatment parameters, such as the introduction of lower irradiance regimens, pain is now uncommonly a major issue. Expected “adverse” effects of a phototoxic insult also include inflammation, manifest as erythema, exudation and sometimes urticaria. Other side‐effects are uncommon and include scarring, altered hair growth or pigmentary change and allergic reactions. The theoretical risk of carcinogenesis with cumulative PDT treatments is unproven and indeed PDT can be considered as a prophylactic approach in high‐risk patients, such as the immunosuppressed. This review summarises the current evidence relating to the adverse effects of topical PDT as part of the guideline updating project on this subject1 and attempts to interpret this evidence in the context of patient risk (Table 1).


  • Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis

    by N.J. Collier, A.K. Haylett, T.H. Wong, C.A. Morton, S.H. Ibbotson, K.E. McKenna, R. Mallipeddi, H. Moseley, D. Seukeran, K.A. Ward, et al.

    Background Topical photodynamic therapy (PDT) is an established treatment option for low‐risk basal cell carcinoma (BCC). Objectives Compare efficacy, cosmesis and tolerability of PDT for BCC with alternative treatments. Methods MEDLINE/PubMed/EMBASE/CENTRAL databases were searched from inception until 1 September 2017. Included studies were randomised controlled trials (RCTs) of PDT for nodular (n) and superficial (s) BCC reporting at least one of the outcomes: clearance at 3 months, and sustained at 1 or 5 years; recurrence at ≥1 year; cosmesis; adverse events; tolerability. Results From 2,331 search results, 15 RCTs (2,327 patients; 3,509 BCCs) were included. PDT efficacy (5‐year sustained clearance) was high although inferior to excisional surgery (nBCC pooled RR 0.76; 95% CI 0.63–0.91), and without re‐treatment of partially‐responding lesions, was modestly inferior to imiquimod (sBCC: RR 0.81; 95% CI 0.70‐0.95) and similar to fluorouracil (sBCC: RR 0.88; 95% CI 0.75‐1.04). Five‐year sustained clearance was inferior with conventional versus fractionated PDT (sBCC: RR 0.76; 95% CI 0.68‐0.84). PDT cosmesis was superior to surgery (sBCC: RR 1.68; 95% CI 1.32‐2.14; nBCC: RR 1.82; 95% CI 1.19‐2.80) and cryosurgery (BCC: RR 3.73; 95% CI 1.96‐7.07), and without re‐treatment of partially‐responding lesions was similar to imiquimod (sBCC: RR 1.01; 95%CI 0.85‐1.19) and fluorouracil (sBCC: RR 1.04; 95% CI 0.88‐1.24). Peak pain was higher but of shorter duration with PDT than topical treatments. Serious adverse reactions were rarer with PDT than imiquimod (sBCC: RR 0.05; 95% CI 0.00‐0.84) and fluorouracil (sBCC: RR 0.11; 95% CI 0.01‐2.04). Combination PDT regimens demonstrated reduced recurrence and improved cosmesis; however, results from these small studies were often non‐significant. Conclusions PDT is an effective treatment for low‐risk BCC, with excellent cosmesis and safety. Imiquimod has higher efficacy than single‐cycle PDT though more adverse effects. Highest efficacy is with excisional surgery. Fractionated and combination PDT options warrant further study.


  • Solar urticaria in 145 patients: Assessment of action spectra and impact on quality of life in adults and children

    by Ann K. Haylett, Dimitra Koumaki, Lesley E. Rhodes

    Summary: Background: Solar urticaria (SU) is a rare chronic inducible urticaria triggered via uncharacterized chromophores. We detail responses of a large patient series to monochromator phototesting and broadband ultraviolet radiation (UVR); relationship to life quality is explored.Methods: Retrospective review of all SU patients undergoing standardized diagnostic photoinvestigation at a specialist centre during 2000‐2016. From 2011, patients completed dermatology life quality index (DLQI) questionnaires for the past week and year.Results: In 145 patients (mean: 35.8, range: 3‐69 years; 18 aged P < .01).Conclusion: SU is predominantly provoked by longer UVA‐shorter visible radiation, which penetrates window‐glass and where sunscreens are less effective; impact on life quality is considerable. Photoprotective agents effective against this spectrum are needed.


  • Open Access

    Comparison of Demographic and Photobiological Features of Chronic Actinic Dermatitis in Patients With Lighter vs Darker Skin Types

    by Ki-Wei Tan, Ann K. Haylett, Tsui C. Ling, Lesley E. Rhodes

    Chronic actinic dermatitis (CAD) is a photosensitivity disorder classically described in older, white men.1 Although the exact cause of CAD remains elusive, increased susceptibility to development of delayed-type allergic responses to endogenous photoallergens and exogenous allergens has been proposed.2 The condition is clinically distinct, defined by a persistent dermatitis and/or pseudolymphomatous eruption affecting predominantly photoexposed sites and by results of monochromator phototesting, which typically show severely reduced minimal erythemal doses (MEDs), especially in the UV-B and shorter UV-A wavelengths.3,4 Chronic actinic dermatitis is associated with multiple contact allergies, including to sesquiterpene lactones, fragrance, colophony, rubber, and sunscreens; however, the association with photocontact allergy is less well known because photopatch testing is less commonly performed. Younger patients,5,6 especially those with darker skin types,7 appear to be increasingly developing CAD, although the prevalence is unknown. We evaluated patients diagnosed with CAD during a 15-year period in a specialized photoinvestigation unit and investigated differences in demographic and photobiological features between patients with lighter and darker skin types.


  • Sunscreen photopatch testing: a series of 157 children

    by A.K. Haylett, Y.Z. Chiang, Z. Nie, T.C. Ling, L.E. Rhodes

    Background Photoprotection including sunscreen use in children is encouraged by health campaigns. While sunscreen chemicals are common causes of photoallergic (PA) contact reactions in adults, limited data are available in children. Objectives To assess the frequency of PA and contact allergy (CA) to sunscreens in children aged < 18 years undergoing investigation for suspected photosensitivity. Methods Retrospective analysis of data on children who underwent photopatch testing to a standard series of nine ultraviolet (UV) filters and to sunscreen products in a single photoinvestigation centre (2000–11). Duplicate series of UV filters and the children's own sunscreen products were applied to the back, with readings taken at sample removal, and at 24 and 48 h after 5 J cm−2 UVA exposure of one series. Results The analysis comprised 157 children (aged 3–17 years, 69 male and 88 female). In total 10 children (6·4%) showed positive photopatch responses to UV filters and/or their sunscreen products (4·5% to UV filters, 5·7% to their sunscreen products). The responsible UV filters most often identified were benzophenone‐3 and octyl methoxycinnamate. Additionally, CA reactions were observed in nine children (5·7%), with 16 children (10·2%) showing PA and/or CA to UV filters and/or sunscreen products. Conclusions This is the largest series of photopatch testing reported in children, and shows that both sunscreen PA and CA are quite frequent in those undergoing photoinvestigation. Photopatch testing should be considered in children presenting with features of photosensitivity.


  • Photodistributed telangiectasia induced by calcium channel blockers: case report and review of the literature

    by Waseem Bakkour, Ann K. Haylett, Neil K. Gibbs, Robert J. G. Chalmers, Lesley E. Rhodes


  • Impact of photosensitivity disorders on the life quality of children

    by Muneeza Rizwan, Ann K. Haylett, Helen L. Richards, Tsui C. Ling, Lesley E. Rhodes

    Summary: Background/Purpose: Abnormal cutaneous sensitivity to the ultraviolet and/or visible radiation in sunlight characterizes photosensitivity disorders. Little is known regarding their impact in childhood. Our objective was to characterize childhood photosensitivity disorders presenting to a photoinvestigation unit, evaluating their impact on quality of life (QoL).Methods: Photoinvestigation records of children attending from 2000 to 2007 were evaluated for diagnosis, clinical, demographic and phototest parameters. These children were subsequently contacted during summertime to evaluate the impact of photosensitivity on QoL, utilizing the children's dermatology life quality index (CDLQI).Results: 83 children underwent photoinvestigation; 62 (74.7%) were diagnosed photosensitive (mean age 8.6 years, range 2–16; 33 female), with abnormal phototest findings in 35 children. 38/55 questionnaires (69.1%) were returned. Mean (± standard deviation) CDLQI score (all diagnoses) was 10.2 ± 7.3 with very high scores in xeroderma pigmentosum (20.7 ± 5.7; n = 3) and actinic prurigo (18.2 ± 7.1; n = 6) and moderate scores in photoaggravated eczema (7.9 ± 4.2; n = 8) and polymorphic light eruption (6.2 ± 4.4 n = 18). CDLQI correlated with number of months affected per year (r = 0.595, P = 0.001).Conclusion: Photosensitivity disorders have a substantial impact, ranging from moderate to extremely large, on QoL in childhood, and the psychological consequences should be considered in their management.


  • Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients

    by A.K. Haylett, S. Felton, D.W. Denning, L.E. Rhodes

    Background Voriconazole, a broad-spectrum triazole antifungal agent increasingly used to treat aspergillosis, has been linked with acute photosensitivity and skin carcinogenesis. The action spectrum of the photosensitivity is unknown, while an indirect retinol effect secondary to the antifungal’s impact on CYP450 enzymes has been proposed to contribute to the underlying mechanism. Objectives To perform a detailed photobiological assessment of the photosensitivity presenting in a series of 12 patients treated with voriconazole. Methods Minimal erythemal dose thresholds (MED) to narrow wavebands of ultraviolet (UV) A, UVB and visible light were determined. Provocation testing was performed to broadband UVA (310–400 nm) and to solar-simulated radiation (SSR) (290–400 nm). Patients underwent routine photopatch testing and laboratory investigations including serum vitamin A (retinol). Results Patients (eight men, four women; median age 54 years, range 40–63) experienced moderate-severe cutaneous erythema (n = 12), burning pain (n = 5), itching (n = 3), scaling (n = 5), vesiculation (n = 5) and oedema (n = 1) following sunlight exposure; increased lentigines (n = 4) and actinic cheilitis (n = 4) were also observed. While the majority (n = 8) of patients showed normal MED thresholds to monochromator phototesting to UVB, UVA and visible light, a low MED to UVA was observed in four patients. Repeated provocation testing with broadband UVA and SSR provoked an abnormal erythema in eight and 10 patients, respectively. Serum retinol levels were mildly elevated in two patients but normal in the majority. Conclusion UVA sensitivity is the predominant finding in acute voriconazole-induced photosensitivity. We found little evidence of elevated circulating retinol as the causal factor. Patients with voriconazole-induced photosensitivity require education in appropriate UVA protective measures in addition to consideration of skin surveillance for malignant sequelae.